ERBB2 and breast carcinoma: In this secondary analysis of data from 565 postmenopausal women with lymph node–negative, estrogen receptor–positive, and ERBB2-negative breast cancer who participated in the Stockholm tamoxifen randomized clinical trial (STO-3), tumor size and tumor grade were significantly associated with long-term (25-year) survival.